<sup>68</sup>Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 27822700.
- Also identified by DOI 10.1007/s00259-016-3563-6 and PMC identifier 5323468.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
To report on imaging findings using <sup>68</sup>Ga-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients. <sup>68</sup>Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. Out of 81 tumor lesions identified, 84% were identified on <sup>68</sup>Ga-PSMA-HBED-CC PET. <sup>68</sup>Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptor-negative lesions. SUV values derived from FDG PET/CT, available in seven patients, and <sup>68</sup>Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p = 0.015). <sup>68</sup>Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry.
Medical subject headings
- Breast Neoplasms
- Carcinoma
- Organometallic Compounds
- Positron Emission Tomography Computed Tomography
- Radiopharmaceuticals